Friday, 18 Jan 2019

You are here

CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis

Qin and colleagues have published in Arthritis & Rheumatology that 40% of people will be affected by symptomatic osteoarthritis in at least one hand.  (Citation source: http://buff.ly/2qTUscZ)  

They analyzed 2,218 adults ≥ 45 years from the Johnston County (NC) Osteoarthritis Project, specifically collecting looking for symptomatic hand OA (SHOA) over two time frames (1999-2004 and 2005-2010). SHOA was defined as having both self-reported symptoms and radiographic OA in the same hand.

The found the lifetime risk of SHOA is 39.8% with greater frequency in women as they age.  Women by age 85 yrs had a 47.2% frequency of SHOA compared to only 24.6% in men.

Hand OA was more common in whites moreso than blacks (41.4% vs 29.2%, respectively). The lifetime risk in the obese was 47.1 percent, compared to 36.1 percent for non-obese people.

Hand OA represents a significant publich health problem for which there are few, if any, credible treatment options.  Dr. Marc Hochberg and coworkers at OARSI have submitted a 103 page "white paper" to  FDA to designate OA as a "Serious Disease", staging that OA is a "serious disease for which there are no current satisfactory treatments". (Citation source: http://buff.ly/2pTuVm1)

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.

NEJM Review - Glucocorticoid-Induced Osteoporosis

Lenore Buckley and Mary Humphrey have published a nice review of glucocorticoid-induced osteoporosis (GIOP) in the NEJM.

Uncertain Long Term Efficacy in Trials of Knee Osteoarthritis

A systematic review and network meta-analysis of 47 randomized clinical trials in knee osteoarthritis finds uncertainty around estimates of effect size for pain scores thereby casting uncertainty over the long-term efficacy of medications for knee osteoarthritis.

Zolendronate Protects Against Fracture in Osteopenia

The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.

While it is known that bisphonates have beneficial effects in osteoporosis, their impact in osteopenia has not been shown.